Vaptans: A new option in the management of hyponatremia
Studies with vaptans support the short-term administration of vaptans (up to 1–2 weeks) and have shown a significant improvement of the low levels of sodium. Short-term studies have also …
Where vaptans do and do not fit in the treatment of hyponatremia
Jun 25, 2012 · Vaptans are efficacious in raising serum sodium in long-standing ‘asymptomatic’ hyponatremia. However, the cost of the only Food and Drug Administration-approved oral …
Vaptans for the treatment of hyponatremia | Nature Reviews ...
Feb 1, 2011 · Vaptan therapy is absolutely contraindicated in hypovolemic hyponatremia (in which total body water is reduced) and is ineffective in the vasopressin-independent form of …
Role of vaptans in the management of hyponatremia - PubMed
Vaptans have been shown to increase serum sodium concentrations in patients with euvolemic or hypervolemic hyponatremia in a reproducible manner, but their safe use requires full …
Where vaptans do and do not fit in the treatment of ...
Apr 1, 2013 · Vaptans are efficacious in raising serum sodium in long-standing ‘asymptomatic’ hyponatremia. However, the cost of the only Food and Drug Administration-approved oral …
Hyponatraemia is an electrolyte disorder defined as a serum sodium concentration ([Na+]) <136 mmol/L and represents a very important clinical and economic issue.
Vaptans and Hyponatremia in Critical Patients - PMC
Vaptans cause “aquaresis”, which results in the correction of plasma osmolality and serum sodium levels, without activation of the renin-angiotensin-aldosterone system or changes in …